BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 17944567)

  • 1. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing targeted therapies for lung cancer.
    Gandara DR
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiogenesis in lung cancer.
    Sandler AB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics and mechanisms of apoptosis in carcinomas of the lung and pleura: therapeutic targets.
    Motadi LR; Misso NL; Dlamini Z; Bhoola KD
    Int Immunopharmacol; 2007 Dec; 7(14):1934-47. PubMed ID: 18039530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second and third line treatment in non-small cell lung cancer.
    Favaretto A; Pasello G; Magro C; Schettino C; Gridelli C
    Crit Rev Oncol Hematol; 2009 Aug; 71(2):117-26. PubMed ID: 19249227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
    Dovedi SJ; Davies BR
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell lung cancer and targeted therapies.
    Blackhall FH; Shepherd FA
    Curr Opin Oncol; 2007 Mar; 19(2):103-8. PubMed ID: 17272981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker targets and novel therapeutics.
    Clouser M; Hess LM; Chambers SK
    Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in preclinical small molecules for the treatment of NSCLC.
    Zhang Q; Feng W; Zhou H; Yan B
    Expert Opin Ther Pat; 2009 Jun; 19(6):731-51. PubMed ID: 19456275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic targets.
    Farley J; Birrer MJ
    Cancer Treat Res; 2009; 149():63-84. PubMed ID: 19763431
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
    Kotteas EA; Charpidou AG; Syrigos KN
    Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiogenesis and lung cancer].
    Pérol M; Arpin D
    Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.